Nyxoah SA (NYXH) Fair Value 2026

NYXH · Medical Devices ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

5.6 /10

32 fundamental signals · 0 models active

Value Trap Risk

LOW (38/100)

Quick Summary — As of 2026-10-07, Nyxoah SA (NYXH) trades at $1.43. QOC: 5.6/10. Value Trap Risk: 38/100 (LOW). 0/13 models active.

Key Facts

Ticker
NYXH
Price
$1.43
Quality Score
5.6/10
Value Trap Risk
38/100
Models Active
0/13
Last Updated
Strength: 0 independent models provide multi-angle coverage
Risk: Limited model coverage (0/13) may reduce confidence

What Fair Value Does Each Model Give NYXH?

0 Intrinsic Value Models vs. Current Price ($1.43)

Core Models (Unlocked)
Model Fair Value Upside

All Models Active

All 0 models are displayed above.

What Is Nyxoah SA (NYXH) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, Nyxoah SA currently lacks sufficient data across our 13-model framework. As more financial data is processed from SEC filings, our models will generate intrinsic value estimates.

What Do the Models Say About NYXH?

0 of 13 models are currently active for NYXH. See which stocks rank higher →

How Does NYXH Rank in Medical Devices?

Among 161 Medical Devices stocks, NYXH ranks #111 by Quality of Company score. CirclFi's QOC score of 5.6/10 evaluates 32 fundamental signals. A score of 5.6 reflects mixed fundamentals.

See all Most Undervalued Medical Devices Stocks →

As a pharmaceutical industry, Nyxoah SA operates in a sector where pipeline depth and stage distribution is a critical driver of valuation. Investors evaluating NYXH should weigh these sector-specific dynamics alongside our model-derived fair values.

Is NYXH a Value Trap?

CirclFi's Value Trap algorithm assigns NYXH a score of 38/100 (LOW). This indicates low risk. The financial profile does not exhibit typical value trap warning signs. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

0 of 13 models are active for Nyxoah SA. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi 32-factor quality framework, Nyxoah SA's fundamental quality profile registers 5.6/10. This respectable score captures the company's profitability depth, growth consistency, balance sheet resilience, and shareholder return track record.

CirclFi runs 13 independent models for each stock. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every NYXH valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Nyxoah SA Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Medical Devices Stocks Should You Also Analyze?

11 related Medical Devices stocks with 13-model coverage

BMRABiomerica, Inc.QOC 5.6NNOXNano-X Imaging Ltd.QOC 5.6COCHEnvoy Medical, Inc.QOC 5.6NXLNexalin Technology, Inc.QOC 5.6QTIQT Imaging Holdings, Inc.QOC 5.6PLSMPulsenmore Ltd.QOC 5.6LUDGLudwig Enterprises, Inc.QOC 3.7GEHCGE HealthCare Technologies Inc.QOC 7.9TMCITreace Medical Concepts, Inc.QOC 6.5IRMDIRADIMED CORPORATIONQOC 9.8PODDInsulet CorporationQOC 9.6

Read investment analysis: BMRA · NNOX · COCH · NXL · QTI · PLSM · LUDG · GEHC · TMCI · IRMD · PODD

Which Other Stocks Have a Similar Quality Score to NYXH?

6 companies across all industries closest to NYXH’s Quality of Company score of 5.6/10.

NHPNational Healthcare Properties, Inc.QOC 5.6FATEFate Therapeutics, Inc.QOC 5.6ACETAdicet Bio, Inc.QOC 5.6QUCYQuantum Cyber N.V.QOC 5.6ASURAsure Software, Inc.QOC 5.6NVDANVIDIA CorporationQOC 10.0

Read investment analysis: NHP · FATE · ACET · QUCY · ASUR · NVDA

Where Does NYXH Sit in CirclFi's Medical Devices Rankings?

NYXH is ranked against every other Medical Devices stock CirclFi covers in each of these screens.

See all Medical Devices stocks ranked →

What Else Do Investors Ask About Nyxoah SA’s Valuation?

What is Nyxoah SA's intrinsic value in 2026?

CirclFi does not yet have enough active models to publish a median fair value for Nyxoah SA (NYXH). The Quality of Company score is 5.6/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is NYXH overvalued or undervalued right now?

At $1.43, 0 of 0 active models suggest NYXH may be undervalued, while 0 indicate potential overvaluation. The assessment depends on which methodology best fits Nyxoah SA's business model in Medical Devices.

What does a Quality of Company score of 5.6 mean for NYXH?

Nyxoah SA's QOC of 5.6/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores between 5-7 reflect moderate fundamentals with areas for improvement.

How many valuation models does CirclFi run on NYXH?

CirclFi analyzes NYXH with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 0 of 13 are active for this stock. Read the full methodology →

Is NYXH a value trap in 2026?

Nyxoah SA's Value Trap score is 38/100 (LOW). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap. Browse stocks by value-trap risk →

Cite this analysis — “CirclFi assigns Nyxoah SA (NYXH) a Quality of Company score of 5.6/10 across 32 fundamental signals as of 2026-10-07.” Source: circlfi.com/stock/NYXH/ · Methodology
Primary sources for this NYXH valuation
  • Financial statements: Nyxoah SA 10-K and 10-Q filings on SEC EDGAR (CIK 0001857190) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for NYXH as of ; valuations recomputed .